In a report released yesterday, Alex Arfaei from BMO Capital maintained a Buy rating on AstraZeneca (AZN), with a price target of $49. The company’s shares opened today at $38.06.
According to TipRanks.com, Arfaei is a 5-star analyst with an average return of 8.2% and a 68.4% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Elanco Animal Health Inc, Merck & Company, and Eli Lilly & Co.
Currently, the analyst consensus on AstraZeneca is a Moderate Buy with an average price target of $59.87.
See today’s analyst top recommended stocks >>
AstraZeneca’s market cap is currently $97.56B and has a P/E ratio of 40.58. The company has a Price to Book ratio of 9.31.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AstraZeneca Plc is a holding company, which engages in the research, development and manufacturing of pharmaceutical products. The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases.
